A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) (NCT06355531)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
🩺 Plain-English Summary (8th-Grade Level)
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Who can join: Review the eligibility criteria below.
Location: The Neurology Center of Southern California - Carlsbad — Carlsbad, California
Age range: 50 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (44 Sites)
Showing the first 25 of 44 sites.
- The Neurology Center of Southern California - Carlsbad — Carlsbad, California
- UCSF Weill Institute for Neurosciences — San Francisco, California
- Rocky Mountain Movement Disorders Center — Denver, Colorado
- University of Miami Miller School of Medicine — Miami, Florida
- Augusta University — Augusta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Quest Research Institute — Farmington Hills, Michigan
- Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Duke Neurology — Durham, North Carolina
- Vanderbilt University Medical Center — Nashville, Tennessee
- Central Texas Neurology Consultants — Round Rock, Texas
- Groupe Hospitalier Pellegrin — Bordeaux,
- Hôpital de la Timone — Marseille,
- L'Hôpital Universitaire Carémeau — Nîmes,
- Hôpital Universitaire Pitié Salpêtrière — Paris,
- Hôpital Pierre-Paul Riquet — Toulouse,
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson — Beelitz,
- Universitätsklinikum Düsseldorf — Düsseldorf,
- Universitätsklinikum Leipzig — Leipzig,
- Ludwig-Maximilians-Universität München (LMU) — Munich,
- Pécsi Tudományegyetem Általános Orvostudományi Kar — Pécs,
- IRCCS Istituto Delle Scienze Neurologiche di Bologna — Bologna,
- Azienda Ospedale Università di Padova — Padova,
- Azienda Ospedaliero-Universitaria Pisana — Pisa,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Progressive Supranuclear Palsy
- Art Therapy in Progressive Supranuclear Palsy — Nashville, Tennessee
- Remote Monitoring in Progressive Supranuclear Palsy (PSP) — Baltimore, Maryland
- tDCS as Treatment for Motor Function — Toronto, Ontario
- A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy — Rochester, Minnesota
Explore by condition: All Progressive Supranuclear Palsy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.